News

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’https://www.google-analytics.com/analytics.js’,’ga’);

ga(‘create’, ‘UA-77332372-1’, ‘auto’);
ga(‘send’, ‘pageview’);

Fesik Lab

News

Fesik wins 2021 Chester Stock Award

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim Expands Collaboration with Vanderbilt University for Difficult-to-Treat Cancers

VU takes key role in cancer drug discovery consortium

Stephen Fesik Receives Grant W. Liddle Award for Outstanding Contributions in Clinical Research

Progress in the Search for Mcl-1-Targeted Anticancer Agents

Cancer: The Ras Renaissance

Grant bolsters pancreatic cancer drug discovery efforts

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Cancer’s Holy Grail: Innovative Method Takes Aim at “Undruggable” Proteins

Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange

Untangling RAS: An “undruggable” cancer-causing protein, 30 years of research and the national initiative that aims to finally make the connections

Stephen W. Fesik presents the W. Dial Black Family Lecture at Baylor University

Discovery of an Inhibitor of Replication Protein A’s Protein-Protein Interactions

Steve Fesik Attended 2nd Annual Great Futures Gala Headed by Martin Sheen in Nashville, TN

Taking Multiple Shots At Drug-Resistant Cancer: Technique directly links fragments to make a variety of small molecules that block hot target Mcl-1

Discovery of Mcl-1 Inhibitors Offer Hope for New Cancer Therapeutics

Grant renewal boosts GI cancer research program

Targeting Cancer Through K-Ras

Reviving Ras

VanderbiltHealth video interview “My Health Chat: Cancer Drug Discovery” with Stephen W. Fesik, Ph.D. and Lawrence J. Marnett, Ph.D.

Stephen W. Fesik, Ph.D., Receives Sixth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Carroll wins Vanderbilt’s first Damon Runyon Fellowship

Huge new magnet to enhance cancer drug discovery efforts

Aileron Therapeutics Appoints Veterans of Life Sciences Industry and Wall Street to its BOD; Nobel Laureate and Venerated Drug Developers Join Company’s SAB

A New Prescription for Drug Discovery

Fesik receives $2.5M grant from the Lustgarten Foundation to support his drug discovery research for the treatment of pancreatic cancer

Fesik is elected the 2010 AAAS Fellow for distinguished contributions in the application of structural biology to medicinal chemistry and drug discovery

Fesik wins NIH Director’s Pioneer Award

Fesik to hold new Ingram Chair in Cancer Research

Fesik Presents the 14th Annual Weinberg Memorial Lecture at Harvard Medical School

Fesik Delivers the Keynote Address at the Joint Keystone Symposia: Computer-Aided Drug Design (Z7) and New Directions in Small Molecule Drug Discovery (Z8)

VUMC’s Fesik lands technology innovation award

More on the Menu: Expanding the Selection of Cancer Therapies

NIH grant bolsters search for new cancer drugs

VU joins effort to develop new cancer therapies

Renowned cancer drug researcher joins Vanderbilt